Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance

Fong, Dominic; Steurer, Michael; Obrist, Peter; Barbieri, Verena; Margreiter, Raimund; Amberger, Albert; Laimer, Klaus; Gastl, Guenther; Tzankov, Alexandar; Spizzo, Gilbert

doi:10.1136/jcp.2006.037333

Cited by 97 publications

(83 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efforts for standardising the immunohistochemical staining and evaluation procedure were explained highlighting an advanced scoring system that reflected both frequency, and intensity of staining. A similar negative correlation between EpCAM expression and survival as previously observed by the group for breast and gall bladder cancer (Varga et al, 2004) was also now observed with ampullary carcinoma of the pancreas (Fong et al, 2006) and for squamous cell cancer of head and neck. N Stoecklein (Duesseldorf, Germany) reported a negative correlation between EpCAM expression and overall survival in patients with squamous cell carcinoma of the oesophagus, a very deadly disease with no established systemic treatment option.…”

Section: Epcam Expression and Survival Prognosis Of Cancer Patientssupporting

confidence: 84%

EpCAM (CD326) finding its role in cancer

Baeuerle¹,

2007

View full text Add to dashboard Cite

Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one of the first tumour-associated antigens identified, it has never received the same level of attention as other target proteins for therapy of cancer. It is also striking that ever since its discovery in the late 1970s the actual contribution of EpCAM to carcinogenesis remained unexplored until very recently. With a First International Symposium on EpCAM Biology and Clinical Application this is now changing. Key topics discussed at the meeting were the frequency and level of EpCAM expression on various cancers and its prognostic potential, the role of EpCAM as an oncogenic signalling molecule for cancer cells, recent progress on EpCAM-directed immunotherapeutic approaches in clinical development and the interaction of EpCAM with other proteins, which may provide a basis for a therapeutic window and repression of its growthpromoting signalling in carcinoma. Future research on EpCAM may benefit from a unified nomenclature and more frequent exchange among those who have been working on this cancer target during the past 30 years and will do so in the future.

show abstract

Section: Epcam Expression and Survival Prognosis Of Cancer Patientssupporting

confidence: 84%

EpCAM (CD326) finding its role in cancer

Baeuerle¹,

2007

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there was only one report regarding the relationship between Ep-CAM expression and the prognosis of pancreatic cancer patients (Fong et al, 2008). According to their opinion, no significant difference was shown in the prognosis between the highand low-Ep-CAM expression in all 153 patients, but in the subgroups of patients with advanced disease, highEp-CAM expression group showed significantly poor prognosis compared with low expression.…”

Section: Discussionmentioning

confidence: 91%

“…In this study, we divided enrolled patients into Ep-CAM high and low-expression group by four of Ep-CAM expression scoring and this cut-off line was based on the previous reports (Gastl et al, 2000;Varga et al, 2004;Fong et al, 2008;Noda et al, 2009). However, as shown in Figure 2, it might not be appropriate to set the cut-off line at four because there were many patients scoring between 4 and 6.…”

Section: Discussionmentioning

confidence: 99%

“…In brief, the proportion score described the estimated fraction of positively stained tumor cells (0, none; 1, o10%; 2, 10-50%; 3, 50-80% and 4, 480%) and the intensity score represented the estimated staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong). The total score was ranging from 0 to 12, and Ep-CAM positive cases represented those with a total score 44 according to previous reported creiteria (Gastl et al, 2000;Varga et al, 2004;Fong et al, 2008;Noda et al, 2009). For the evaluation of heterogeneity in pancreatic cancer, the average score of triplicate tissues from each patient was used.…”

Section: Patient Enrollmentmentioning

confidence: 99%

See 1 more Smart Citation

Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity

et al. 2011

View full text Add to dashboard Cite

“…We recently showed that EpCAM (TROP1, GA733-2) overexpression predicts poor survival in different cancer entities. [14][15][16] Interestingly, expression of TROP2 did not correlate with EpCAM expression. 17 Anti-EpCAM antibodies can cause significant reduction in mortality and relapse rates of resected colon cancer patients following treatment with the EpCAM-specific monoclonal antibody edrecolomab.…”

Section: Discussionmentioning

confidence: 96%

TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity

et al. 2008

View full text Add to dashboard Cite

Squamous cell carcinoma is by far the most common type of cancer of the oral cavity, representing more than 90% of all oral cancers. Despite refinement of surgical techniques and adjuvant therapies, the prognosis for patients with oral squamous cell carcinoma remains poor. Identification of prognostic factors related to tumor biology might improve this assessment. Recently, the human trophoblast cell-surface antigen TROP2 was found to be highly expressed in colorectal cancer, correlating with aggressiveness and poor prognosis. Thus, the aim of this study was to investigate TROP2 expression and its prognostic impact in oral squamous cell carcinoma patients. TROP2 expression was examined by immunohistochemistry in a series of 90 patients on a tissue microarray of paraffin-embedded specimens. Survival was calculated using Kaplan-Meier estimates. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. TROP2 overexpression was observed in 52 (58%) of the tumor samples. Kaplan-Meier curves showed that TROP2 overexpression was significantly associated with decreased overall survival (Po0.01). Overall survival gradually worsened with increasing TROP2 scores. By univariate analyses, no correlation with conventional clinicopathological features was found. Multivariate Cox regression analysis revealed TROP2 overexpression to be an independent factor predictive of poor disease outcome (Po0.01). These results demonstrate that TROP2 overexpression is an independent prognostic marker in patients with oral squamous cell carcinoma. TROP2 overexpression was detectable in 58% of the tumor samples, indicating it to be a potential novel therapeutic target in squamous cell carcinoma of the oral cavity.

show abstract

Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance

Cited by 97 publications

References 24 publications

EpCAM (CD326) finding its role in cancer

EpCAM (CD326) finding its role in cancer

Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity

TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity

Contact Info

Product

Resources

About